Answers are grounded in this paper and cite their sources.
Activated phosphoinositide 3-kinase delta syndrome 1 and 2 (APDS1, APDS2) are rare gain-of-function inborn errors of immunity (IEI) leading to recurrent severe infections, bronchiectasis, lymphoproliferation and lymphoma. APDS1 and APDS2 are caused by mutations in PIK3CD and PIK3R1 respectively, which together encode the subunits of the phosphoinositide 3-kinase enzyme (PI3K). The only curative therapy is allogeneic hematopoietic stem cell transplantation (alloHSCT), which requires a suitable donor and incurs a significant risk of morbidity and mortality. An adenine base editing strategy was developed to target the most frequent point mutations in APDS1 (p.E1021K, c.3061G>A; ~90% of patients) and APDS2 (c.1425+1G > A; ~50% of patients). Highly efficient correction of the pathogenic point mutation was achieved in patient T cells and hematopoietic stem cells (HSCs) and associated with functional restoration of PI3K signaling, rescue of the activation-induced cell death phenotype and, in APDS2, abrogated expression of the pathogenic splice isoform. Edited HSCs maintained pluripotency and achieved long-term engraftment in immunodeficient mice. A healthy control:APDS1 mixed chimera mouse model suggested that 75% wild-type engraftment generated a wild-type phenotype with respect to T and B cell dysfunction and lymphoproliferation, and thus similar editing efficiencies would be predicted to improve patient clinical phenotype. Together, these data demonstrate successful application of base editing to a gain-of-function IEI, with potential for application in other diseases.
No takes yet. Share an insight, caveat, or question.
Orf et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: